Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: fda approves + fda approved + zemplar  Related to the article below (Last Update: 7/1/2008)

FDA Approves First Generic Risperidone to Treat Psychiatric Conditions
FDA.gov -
Risperdal, and other antipsychotic medications, are not FDA-approved to treat dementia-related psychosis. The decision to use antipsychotic medications in ...
UPDATE 1-Teva wins US approval for generic Risperdal Reuters
2nd UPDATE: Teva, After FDA OK, Launches Generic Risperdal CNNMoney.com
all 40 news articles »  TEVA - JNJ

HealthNewsDigest.com
US FDA approves Pfizer injectable pet antibiotic
Reuters -
This is the third Pfizer animal drug approved by the US Food and Drug Administration since early 2007. The FDA approved Cerenia, a motion sickness pill for ...
Pfizer gets FDA approval for new one-dose antibiotic for dogs and cats MLive.com
Pfizer gains FDA approval for pet antibiotic CNNMoney.com
FDA approves Pfizer's animal antibiotic Hays Pharma
Business Wire (press release) - RTT News
all 22 news articles »  PFE
Crystalens HD(TM) Receives FDA Approval
FOXBusiness -
The Crystalens HD is the fourth generation of the only FDA approved accommodating lens. The surface of the Crystalens HD has been shaped to enhance the ...
FDA Might Approve Nebido If Indevus Addresses Deficiencies
Wall Street Journal -
Its struggles with Nebido come at a time when pharmaceutical companies are increasingly facing shortening pipelines amid a growing list of FDA-approval ...
FDA: Older psych drugs may be dangerous to seniors suffering from ... Wilkes Barre Times-Leader
all 6 news articles »  IDEV

FinFacts Ireland
As FDA Focuses on Safety, Fewer New Drugs Are Approved
Wall Street Journal Blogs, NY -
Janet Woodcock, head of the FDA?s Center for Drug Evaluation and Research, notes that new drug applications submitted to the FDA by the industry dropped 33% ...
Markets News Monday: Oil price above $142 in New York and London ... FinFacts Ireland
all 8 news articles »
FDA approves Pfizer antibiotic for cats, dogs
Detroit Free Press, United States - 19 minutes ago
BY MEGHANA KESHAVAN ? FREE PRESS BUSINESS WRITER ? July 1, 2008 The FDA has approved a single-dose antibiotic from Pfizer Inc. for cats and dogs, ...PFE
OrthoNeutrogena says FDA approves collagen-based facial filler ...
Forbes, NY -
SAN FRANCISCO (Thomson Financial) - OrthoNeutrogena said Monday the Food and Drug Administration has approved its collagen-based facial filler Evolence for ...
FDA Approves EVOLENCE ? , a New Generation Collagen-Based Facial ... Business Wire (press release)
all 12 news articles »

ABC News
GlaxoSmithKline responds to FDA's Cervarix questions
Bizjournals.com, NC -
The FDA approved Merck & Co. Inc.'s cervical cancer vaccine Gardasil in 2006. Last week the FDA rejected expanding the use of Gardasil for women ages 27 to ...
Cervarix Approval By The FDA Might Be Delayed eFluxMedia
FDA Rejects Gardasil for Older Women MedHeadlines
Approval of Glaxo's Cervarix vaccine delayed Food Consumer
CNNMoney.com - Newsinferno.com
all 206 news articles »  GSK
Introgen seeks FDA approval for 'groundbreaking' cancer drug
Austin American-Statesman, TX -
Last year, the agency approved 19 new drugs, a 24-year low, according to the Wall Street Journal. "The FDA is the moving target," Dunn said. ...
Introgen stock rises as company seeks FDA approval of cancer drug Bizjournals.com
Introgen Submits ADVEXIN ? Regulatory Applications in the US and ... Business Wire (press release)
Introgen shares rise on cancer drug filings CNNMoney.com
CNNMoney.com
all 27 news articles »  INGN - TSE:DDS - DDSS
UCB files for approval to EMEA for Cimzia in rheumatoid arthritis ...
Forbes, NY -
... (FDA) in February for approval of Cimzia in the treatment of adult patients with active rheumatoid arthritis. On April 22, the FDA approved the drug in ...
UCB's Cimzia? filed with EMEA for treatment of rheumatoid arthritis Ad-Hoc-News (Pressemitteilung)
UPDATE 1-UCB seeks go-ahead for Cimzia on arthritis Reuters
all 14 news articles »
Source: Google News

Vitamin D2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome -
HP Koeffler, N Aslanian, JO?Kelly - Leukemia Research, 2005 - Elsevier
... Paricalcitol [19-nor-1,25(OH) 2 D 2 , Zemplar] has been approved by the
FDA for treatment of secondary hyperparathyroidism. This ...

[PDF] The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era -
KI Kaitin, EM Healy - Drug Information Journal, 2000 - diahome.org
... por- tions of the NDA were reviewed by FDA For NCEs ... NDA NDA Approval Submission Approval
Phase ... Products Approved in 1998 Abacavir (Ziagen) A Glaxo Wellcome P 6 ...
-

FDA Approves Ketek, Cardizem, KyphX HV-R, Oxycodone Risk Management Plan, Quinaretic, and Zemplar
Y Waknine - medscape.com
... The FDA recently approved two generic ... While the approval should make oxycodone HCl
a safe and effective medicine available at lower cost to patients ...

FDA Approves Ketek, Cardizem, KyphX HV-R, Oxycodone Risk Management Plan, Quinaretic, and Zemplar
CME Medscape, M Connect, C Care, G Surgery, M … - medscape.com
... The FDA recently approved two generic ... While the approval should make oxycodone HCl
a safe and effective medicine available at lower cost to patients ...

FDA Approvals: Zemplar Capsules, Arixtra, Glumetza
Y Waknine - medscape.com
... On May 26, the FDA approved a capsule formulation of paricalcitol (Zemplar, made
by Abbott ... The approval was based on the results of three multicenter ...

FDA Approvals: Zemplar Capsules, Arixtra, Glumetza
CME Medscape, M Connect, C Care, G Surgery, M … - medscape.com
... On May 26, the FDA approved a capsule formulation of paricalcitol (Zemplar, made
by Abbott ... The approval was based on the results of three multicenter ...

FDA approves capsule form of paricalcitol
CME Medscape, M Connect, C Care, G Surgery, M … - medscape.com
FDA approves capsule form of paricalcitol. ... Laboratories announced Friday it has received
FDA approval for a capsule form of paricalcitol (Zemplar) for the ...

[CITATION] FDA approves capsule form of paricalcitol
T Month, P Months

FDA Safety Labeling Changes: Arixtra and Alora -
Y Waknine - medscape.com
... On May 26, the FDA approved revisions to the safety labeling for fondaparinux
sodium injection (Arixtra, made by GlaxoSmithKline) to advise of ...

[PDF] ORAL IRON CHELATORS
OI CHELATOR - Proposed Preferred Drug List - tennessee.fhsc.com
... not requiring prior approval ? Verify via ... literature or an FDA approved indication
exists ... calcitriol) HECTOROL?(doxercalciferol) ZEMPLAR?(paricalcitriol) DHT ...

Source: Google Scholar
 
 

FDA approves Zemplar capsules for earlier treatment of kidney disease complication

 
 
The FDA ( Food and Drug Administration ) has approved Zemplar ( Paricalcitol ) capsules, an oral, activated vitamin D therapy for prevention and treatment of secondary hyperparathyroidism ( SHPT ).

Zemplar capsules are indicated for the prevention and treatment of SHPT in stages three and four chronic kidney disease ( CKD ) patients, before the need for dialysis or transplantation.

SHPT is a major complication associated with CKD that can detrimentally impact bones and other vital organs, including the heart, muscles and nerves if left untreated.
It can occur when kidneys lose their ability to activate vitamin D obtained through diet and other sources.
One in nine adults in the U.S., or 20 million people have CKD and another 20 million are at risk for developing CKD from underlying causes such as diabetes and hypertension.

" Until now, physicians have had limited treatment options to manage secondary hyperparathyroidism in earlier-stage CKD patients. Zemplar capsules represent the opportunity to treat this population with a convenient, safe and effective activated vitamin D therapy," said Daniel W. Coyne, at Washington University School of Medicine and lead investigator for the Zemplar capsules Phase III studies.

Zemplar capsules are a new, oral formulation of Zemplar injection, which was introduced in 1998 and is the most widely-used activated vitamin D for the prevention and treatment of SHPT among dialysis patients.

Zemplar capsules were designed to reduce parathyroid hormone levels ( PTH ) with minimal impact on calcium and phosphorus levels in a convenient oral form.
Reduction of PTH is a key indicator of treatment efficacy.
Clinical trial results show that Zemplar capsules had minimal impact on calcium and phosphorus levels when compared to placebo.

The National Kidney Foundation guidelines recommend testing for and treating SHPT early in CKD, well before the need for dialysis. Earlier management of CKD and its complications may reduce the devastating consequences of the disease, such as bone loss and cardiovascular events.

Study results from three Phase III trials showed that Zemplar capsules are safe and effective in reducing parathyroid hormone (PTH) levels in stage three and four kidney disease patients with SHPT.
Ninety-one percent of patients treated with Zemplar capsules had significant and sustained reduction in PTH levels, compared to only 13 percent of placebo patients, after 24 weeks of therapy.
Significant reduction in PTH was defined as achievement of at least two consecutive, greater than or equal to 30 percent reductions in PTH.
Additionally, patients had a greater than 30 percent mean reduction in PTH by week nine, with a sustained reduction in PTH noted throughout the remainder of the study.

The Phase III trial data were further analyzed to evaluate consistency with the National Kidney Foundation in the Kidney Disease Outcomes Quality Initiative ( K/DOQI ) guidelines for calcium and phosphorus targets.
Calcium, phosphorus and calcium and phosphorus product ( Ca X P ) values were maintained within the K/DOQI targets for: calcium ( 91 percent Paricalcitol vs. 95 percent placebo ), phosphorus ( 70 percent Paricalcitol vs. 75 percent placebo ) and calcium and phosphorus combined ( 94 percent Paricalcitol vs. 96 percent placebo ).
Maintaining appropriate levels of calcium and phosphorus is critical for the effective management of SHPT.
Bone disease is a known complication of SHPT that occurs as the kidneys gradually lose their ability to produce activated vitamin D, which is necessary for bone health.

Phase III clinical trials for Zemplar capsules included patients in stages three ( moderate ) and four ( severe ) of chronic kidney disease, who were treated and evaluated in three prospective, randomized, placebo-controlled, double-blinded studies at multiple centers over a 24-week period.
According to the National Kidney Foundation, more than 20 million Americans – one in nine adults – have CKD and an additional 20 million are at risk, creating what the National Institutes of Health describes as a "growing epidemic."
Two major risk factors for kidney disease are diabetes and hypertension, which account for two-thirds of new cases each year.
When kidneys start to fail, they gradually lose their ability to activate the vitamin D they obtain through diet and other sources.
As a result, many kidney patients develop SHPT, a serious disorder that causes bone disease and can affect many organs and tissues, including red blood cells, the heart, nerves and muscles.
If SHPT is not managed early it can worsen, leading to other related conditions and progression of the underlying kidney disease.

The safety profile of Zemplar was similar to placebo. Zemplar is contraindicated in patients with vitamin D toxicity, hypercalcemia, or hypersensitivity to any product ingredient.

PTH, calcium and phosphorus levels should be monitored every three months and more frequently during dosage changes.
Dosage titration is required to reach optimum reduction/levels of PTH.
Excessive administration of vitamin D compounds, including Zemplar capsules, can cause oversuppresion of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.

Source: Abbott, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page